Glaxo Group Limited and Anr. v. Indkus Biotech India and Ors.
Case brief
What is this about?
Delhi High Court, CS(COMM) 321/2024 (& I.A. 8823/2024), decided 04.02.2026 by Justice Jyoti Singh. Commercial IP suit — trade mark infringement, copyright infringement and passing-off — by Glaxo Group Limited against Indkus Biotech India over marks BETASOL, TEEBACT, CEFTOL versus BETNESOL, T-BAC, CEFTUM. Resolved by out-of-court amicable settlement: Defendants agreed to suffer permanent injunction and pay Rs. 5,00,000/- (five lakh rupees) in full and final settlement; suit decreed in terms of settlement and prayers (a)-(d) of paragraph 66 of the plaint; seized goods ordered destroyed on 18.02.2026; suit disposed of with pending application. Useful for settlement-decree practice, superdari/destruction of seized infringing goods, and ex-parte ad interim injunction continuity.
What did the court decide?
Suit decreed in terms of the parties' settlement and prayers (a), (b), (c) and (d) of paragraph 66 of the plaint; Defendants bound not to manufacture/sell/advertise/market the impugned goods under the impugned marks and to pay Rs. 5 lakhs in full and final settlement; seized impugned goods (on superdari with Plaintiffs) to be destroyed on 18.02.2026; Registry directed to draw up the decree sheet; suit disposed of along with the pending application (I.A. 8823/2024).